trending Market Intelligence /marketintelligence/en/news-insights/trending/q5GGmkxtHFH9MQpzNS7LcQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Oxford Immunotec to repurchase $100M ordinary shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Oxford Immunotec to repurchase $100M ordinary shares

Oxford Immunotec Global PLC said its board approved the repurchase up to $100 million of the company's ordinary shares within a five-year period.

The share repurchase program, intended to enhance shareholder value, is subject to shareholder approval at the company's annual general meeting scheduled for June 18.

The transaction will be financed using some of the proceeds from the sale of Oxford Immunotec's U.S. laboratory services business in November 2018, CEO Peter Wrighton-Smith said.

U.K.-based Oxford Immunotec is a diagnostics company focused on developing and commercializing proprietary tests for underserved immune-regulated conditions.